There was no significant difference in OS ( hazard ratio ( HR ) 0.98 ; 95 % confidence interval ( CI ) , 0.67-1 .44 ; P = .453 ) ; median OS was 8.4 months with gemcitabine plus trametinib and 6.7 months with gemcitabine plus placebo .